Condition: Metastatic Pancreatic Neuroendocrine Tumor · Pancreatic Neoplasm · Stage III Pancreatic Neuroendocrine Tumor AJCC v8 · Sponsor: National Cancer Institute (NCI)
This phase I trial tests the safety, side effects, and best dose of sunitinib malate in combination with lutetium Lu 177 dotatate in treating patients with pancreatic neuroendocrine tumors. Sunitinib malate is in a class of medications called kinase inhibitors and a form of targeted therapy that blocks the action of abnormal proteins called VEGFRs that signal tumor cells to multiply. This helps stop or slow the spread of tumor cells. Radioactive drugs, such as lutetium Lu 177 dotatate, may carry radiation directly to tumor cells and not harm normal cells. It is also a form of targeted therapy because it works by attaching itself to specific molecules (receptors) on the surface of tumor cells, known as somatostatin receptors, so that radiation can be delivered directly to the tumor cells and kill them. Giving sunitinib malate and lutetium Lu 177 dotatate in combination may be safer and more effective in treating pancreatic neuroendocrine tumors than giving either drug alone.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| City of Hope Comprehensive Cancer Center | Duarte, California, United States | Active Not Recruiting |
| UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care | Irvine, California, United States | Recruiting |
| UC Irvine Health/Chao Family Comprehensive Cancer Center | Orange, California, United States | Recruiting |
| Memorial Hospital East | Shiloh, Illinois, United States | Recruiting |
| Siteman Cancer Center at Saint Peters Hospital | City of Saint Peters, Missouri, United States | Recruiting |
| Siteman Cancer Center at West County Hospital | Creve Coeur, Missouri, United States | Recruiting |
| Washington University School of Medicine | St Louis, Missouri, United States | Recruiting |
| Siteman Cancer Center-South County | St Louis, Missouri, United States | Recruiting |
| Siteman Cancer Center at Christian Hospital | St Louis, Missouri, United States | Recruiting |
| University Health Network-Princess Margaret Hospital | Toronto, Ontario, Canada | Active Not Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05687123